Can Eliquis and Plavix Be Used Together?
Yes, Eliquis (apixaban) and Plavix (clopidogrel) can be used together, but this combination significantly increases bleeding risk and should only be used when there is a clear indication requiring both anticoagulation and antiplatelet therapy—most commonly in patients with atrial fibrillation who undergo percutaneous coronary intervention (PCI) or have acute coronary syndrome (ACS).
When This Combination Is Appropriate
The primary scenario where combining apixaban and clopidogrel is justified is in patients with atrial fibrillation requiring oral anticoagulation who also need antiplatelet therapy after coronary stenting or ACS 1, 2, 3.
Recommended Regimens
For AF patients undergoing PCI or with ACS:
Initial period (immediately post-PCI): Triple therapy with aspirin 81 mg + clopidogrel 75 mg + apixaban 5 mg twice daily 2
- Aspirin can be discontinued as early as the day following PCI or continued up to 6 months depending on ischemic versus bleeding risk 2
After aspirin discontinuation: Dual antithrombotic therapy (DAT) with apixaban 5 mg twice daily + clopidogrel 75 mg daily for up to 12 months 1, 2
Beyond 12 months: Apixaban monotherapy at the full stroke prevention dose (5 mg twice daily, or 2.5 mg twice daily if dose reduction criteria are met) 1, 4
Dose Adjustments
Standard apixaban dosing when combined with clopidogrel: 5 mg twice daily 1
Reduce apixaban to 2.5 mg twice daily if the patient meets ≥2 of the following criteria 5:
- Age ≥80 years
- Body weight ≤60 kg
- Serum creatinine ≥1.5 mg/dL
Critical Bleeding Risk Considerations
The AUGUSTUS trial demonstrated that apixaban-based dual therapy (apixaban + clopidogrel without aspirin) significantly reduces major bleeding compared to traditional triple therapy 1. Specifically:
- Apixaban reduced bleeding events versus warfarin (HR 0.44,95% CI 0.28-0.68) 1
- Omitting aspirin from the regimen reduced bleeding without increasing thrombotic events 1
Meta-analysis data shows that adding oral anticoagulants to dual antiplatelet therapy more than doubles bleeding risk (HR 2.34,95% CI 2.06-2.66) 6. When combined with aspirin alone, bleeding risk increases by 79% (HR 1.79,95% CI 1.54-2.09) 6.
When This Combination Should NOT Be Used
Do not combine apixaban and clopidogrel in the following situations:
- Atrial fibrillation without recent PCI or ACS: Use apixaban monotherapy for stroke prevention 3, 5
- Stable coronary artery disease without AF: Use clopidogrel or aspirin monotherapy, not anticoagulation 4
- High bleeding risk patients (ARC-HBR criteria) without compelling ischemic indication: Consider shorter duration or avoid combination 1, 4
- Active pathological bleeding: Contraindicated per FDA labeling 7, 8
Duration of Combination Therapy
The duration should be tailored to bleeding and ischemic risk 1, 2:
- Minimum duration: 1 month after bare-metal stent, 3 months after drug-eluting stent 2
- Standard duration: Up to 6 months for most patients 1
- Extended duration (up to 12 months): May be considered in patients with high ischemic risk and low bleeding risk 1
Important Drug Interactions
Avoid combining apixaban with strong dual P-glycoprotein and CYP3A4 inhibitors when already on the 2.5 mg twice daily dose 7. If the patient is on apixaban 5 mg twice daily, reduce to 2.5 mg twice daily when combined with drugs like ketoconazole, itraconazole, or ritonavir 7.
For clopidogrel, avoid omeprazole and esomeprazole as they significantly reduce clopidogrel's antiplatelet activity through CYP2C19 inhibition 8. Use alternative proton pump inhibitors if gastric protection is needed 4, 9.
Monitoring and Management
- No routine coagulation monitoring is required for apixaban 10, 5
- Assess renal function before initiation and at least annually 11, 5
- Reevaluate the need for combination therapy at regular intervals, particularly at 1,3,6, and 12 months 1, 2
- Consider gastric protection with a proton pump inhibitor (other than omeprazole/esomeprazole) in patients at high risk for GI bleeding 4, 9
Key Pitfall to Avoid
The most common error is continuing triple therapy (aspirin + clopidogrel + apixaban) beyond the immediate post-PCI period. Current evidence strongly supports early aspirin discontinuation to minimize bleeding while maintaining antithrombotic efficacy 1, 2. The default strategy should be to transition to dual therapy (apixaban + clopidogrel) as soon as clinically appropriate, typically within days to weeks after PCI 1.